Carlsmed (NASDAQ:CARL) Upgraded to Hold at Wall Street Zen

Carlsmed (NASDAQ:CARL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

A number of other research analysts also recently weighed in on CARL. Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a research report on Monday, December 22nd. Truist Financial reiterated a “buy” rating and issued a $20.00 price objective (up previously from $18.00) on shares of Carlsmed in a research note on Friday, November 7th. BTIG Research reissued a “buy” rating and issued a $24.00 target price on shares of Carlsmed in a research report on Monday, December 15th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Carlsmed in a research report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Carlsmed currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.33.

Carlsmed Stock Performance

CARL opened at $10.95 on Friday. Carlsmed has a fifty-two week low of $10.65 and a fifty-two week high of $17.19. The firm’s 50-day moving average is $12.69. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.91 and a current ratio of 12.03. The company has a market capitalization of $291.16 million and a price-to-earnings ratio of -3.28.

Institutional Investors Weigh In On Carlsmed

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of Carlsmed during the third quarter worth $33,000. JPMorgan Chase & Co. bought a new stake in shares of Carlsmed during the 3rd quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Carlsmed during the 3rd quarter worth about $42,000. Rhumbline Advisers bought a new position in Carlsmed in the 3rd quarter worth about $79,000. Finally, Wells Fargo & Company MN grew its holdings in Carlsmed by 61.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock valued at $97,000 after buying an additional 2,989 shares in the last quarter.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).